

CONSOLIDATED		STANDALONE		
Quarter Ended on 30 th June 2011	Year Ended on 31 st March 2011	Particulars	Quarter Ended on 30 th June 2011	Year Ended on 31 st March 2011
(Reviewed)	(Audited)		(Reviewed)	(Audited)
		1 (a) Net Sales / Income from Operations		
20723	78805	Domestic	20723	78805
13749	41859	Exports	11551	38147
34472	120664	Total	32274	116952
145	766	Less : Excise Duty	145	766
34327	119898	Net Sales / Income from Operations	32129	116186
40	306	(b) Other Operating Income	40	306
34367	120204	Total Income	32169	116492
		2 Expenditure		
-1174	-472	(a) Decrease/(increase) in stock in trade and work in progress	-1174	-472
11802	43494	(b) Consumption of Raw Materials & Packing Materials	11802	43494
6545	16018	(c) Purchase of traded goods	4556	12857
3945	14149	(d) Employees' Cost	3945	14149
1209	4714	(e) Research and Development Expense	1209	4714
-8	664	(f) Excise Duty	-8	664
7013	25612	(g) Other Expenditure	6909	25513
29332	104179	Total	27239	100919
5035	16025	3 Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	4930	15573
8	8	4 Other Income	8	8
5043	16033	5 Profit/(Loss) before Interest, Depreciation, & Exceptional Items	4938	15581
819	2959	6 Depreciation	819	2959
677	2389	7 Interest (Net)	677	2389
3547	10685	8 Profit/(Loss) after Interest but before Exceptional Items	3442	10233
0	0	9 Exceptional Items	0	0
3547	10685	10 Net Profit / (Loss) from Ordinary Activities before Tax	3442	10233
723	1864	11 Tax Expense		
68	282	Less : Provision for Current Tax	711	1801
2756	8539	(Less)/Add : Provision for Deferred Tax (Liability)/Assets	68	282
3770	3770	12 Net Profit / (Loss) from Ordinary Activities after Tax	2663	8150
-	25758	13 Paid up Equity Share Capital	3770	3770
-	2333	(Face value of share Rs 2/-)		
1.46	4.53	14 Reserves excluding Revaluation Reserve	-	23851
-	0.86	15 Debenture Redemption Reserve	-	2333
-	2.76	16 Basic & Diluted EPS (Not Annualised)	1.41	4.32
-	9.96	17 Debt Equity Ratio	-	0.81
		18 Debt Service Coverage Ratio	-	2.68
		19 Interest Service Coverage Ratio	-	9.66
		20 Public Shareholding		
48763089	48763089	- Number of Shares	48763089	48763089
25.87	25.87	- Percentage of Shareholding	25.87	25.87
		21 Promoters and Promoter Group Shareholding		
		(a) Pledged / Encumbered		
		Number of Shares	-	-
		Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	-	-
		Percentage of Shares (as a % of the total share capital of the Company)	-	-
		(b) Non - Encumbered		
139752825	139752825	Number of Shares	139752825	139752825
100.00	100.00	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00
74.13	74.13	Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13

Notes :

1 The above results, which includes unaudited results of the Subsidiary, have been duly reviewed by Statutory Auditors were recommended by by the Audit Committee and were approved by Board of Directors. The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement. The Standalone Financial Results are available on the company's website viz www.alembic-india.com.

2 This being the first quarter of the Company after the demerger becoming effective on 1st April, 2011, the comparable figures for the corresponding quarter of the previous financial year are not available and not given. However, the sales figures of the pharmaceuticals undertaking for the quarter of the previous final year are as under:

Particulars	(Rs.in Lacs)	
	For the quarter ended on 30.06.11	For the quarter ended on 30.06.10
Sales	34472	25662

3 The Company has made listing application with the Bombay Stock Exchange Limited (BSE) and the National Stock Exchange of India Limited (NSE). Both BSE and NSE have given listing permission vide letter dated 16th May, 2011 and 31st May, 2011 respectively. SEBI Permission for relaxation under rule 19 (2) (b) of Securities Contract (Regulation) Act, 1956 is awaited. On receipt of the said permission from SEBI, BSE and NSE will give trading permission.

4 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17).

5 Details of Investor's Complaints for the quarter ended on 30th June, 2011 : Unresolved at the beginning of the quarter-NIL Received during the quarter-NIL, Disposed off during the quarter-NIL, Unresolved at the end of the quarter - Nil

For Alembic Pharmaceuticals Limited

Place : Vadodara
Date : 26th July, 2011

Chirayu Amin
Chairman and Managing Director

Visit us at www.alembic-india.com